45. Identification of predicted neoantigen vaccine candidates in follicular lymphoma patients

      There is a need for new follicular lymphoma (FL) therapies without long-term complications of chemotherapy and with curative potential. We hypothesize that FL contains tumor-specific mutant antigens (TSMAs) that can be targeted by the immune system by vaccination.
      To read this article in full you will need to make a payment


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect